Do coronavirus vaccine challenge trials have a distinctive generalisability problem?
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Other content recommended for you
- COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement
- Comparison of T-cell immune responses to SARS-CoV-2 spike (S) and nucleocapsid (N) protein using an in-house flow-cytometric assay in laboratory employees with and without previously confirmed COVID-19 in South Africa: nationwide cross-sectional study
- Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy
- Vaccine ethics: an ethical framework for global distribution of COVID-19 vaccines
- Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia
- Cohort profile: Stop the Spread Ottawa (SSO)—a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination
- UK Research Ethics Committee’s review of the global first SARS-CoV-2 human infection challenge studies
- Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study
- Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study
- Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?